Batson Sarah, Sutton Alex, Abrams Keith
DRG Abacus, 6 Talisman Business Centre, Talisman Road, Bicester, United Kingdom, OX26 6HR.
Department of Health Sciences, University of Leicester, Centre for Medicine, University Road, Leicester, United Kingdom, LE1 7RH.
PLoS One. 2016 Aug 25;11(8):e0161864. doi: 10.1371/journal.pone.0161864. eCollection 2016.
Patients with atrial fibrillation are at a greater risk of stroke and therefore the main goal for treatment of patients with atrial fibrillation is to prevent stroke from occurring. There are a number of different stroke prevention treatments available to include warfarin and novel oral anticoagulants. Previous network meta-analyses of novel oral anticoagulants for stroke prevention in atrial fibrillation acknowledge the limitation of heterogeneity across the included trials but have not explored the impact of potentially important treatment modifying covariates.
To explore potentially important treatment modifying covariates using network meta-regression analyses for stroke prevention in atrial fibrillation.
We performed a network meta-analysis for the outcome of ischaemic stroke and conducted an exploratory regression analysis considering potentially important treatment modifying covariates. These covariates included the proportion of patients with a previous stroke, proportion of males, mean age, the duration of study follow-up and the patients underlying risk of ischaemic stroke.
None of the covariates explored impacted relative treatment effects relative to placebo. Notably, the exploration of 'study follow-up' as a covariate supported the assumption that difference in trial durations is unimportant in this indication despite the variation across trials in the network.
This study is limited by the quantity of data available. Further investigation is warranted, and, as justifying further trials may be difficult, it would be desirable to obtain individual patient level data (IPD) to facilitate an effort to relate treatment effects to IPD covariates in order to investigate heterogeneity. Observational data could also be examined to establish if there are potential trends elsewhere. The approach and methods presented have potentially wide applications within any indication as to highlight the potential benefit of extending decision problems to include additional comparators outside of those of primary interest to allow for the exploration of heterogeneity.
心房颤动患者发生中风的风险更高,因此治疗心房颤动患者的主要目标是预防中风发生。有多种不同的中风预防治疗方法可供选择,包括华法林和新型口服抗凝剂。先前关于新型口服抗凝剂用于心房颤动中风预防的网状荟萃分析承认纳入试验存在异质性限制,但尚未探讨潜在重要的治疗修饰协变量的影响。
使用网状荟萃回归分析探讨心房颤动中风预防中潜在重要的治疗修饰协变量。
我们对缺血性中风的结局进行了网状荟萃分析,并考虑潜在重要的治疗修饰协变量进行了探索性回归分析。这些协变量包括既往有中风病史的患者比例、男性比例、平均年龄、研究随访时间以及缺血性中风的潜在风险。
所探讨的协变量均未影响相对于安慰剂的相对治疗效果。值得注意的是,将“研究随访”作为协变量进行探索支持了这样一种假设,即尽管网络中各试验的持续时间存在差异,但在该适应症中试验持续时间的差异并不重要。
本研究受可用数据量的限制。有必要进行进一步调查,而且由于证明进一步试验可能困难,因此希望获得个体患者水平的数据(IPD),以便努力将治疗效果与IPD协变量相关联,从而研究异质性。也可以检查观察性数据,以确定其他地方是否存在潜在趋势。所提出的方法和手段在任何适应症中都可能有广泛应用,以突出将决策问题扩展到包括主要关注对象之外的其他比较对象的潜在益处,从而允许探索异质性。